Given that concomitant Aβ and tau pathology is frequent in Lewy-body disease, particularly DLB and PD with dementia, selectivity for α-syn over Aβ and tau is a requirement for a fit-for-purpose α-syn PET radioligand. The gene discussed is MAPT; the disease is Lewy body dementia.